Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a shareholder update on March 13, 2026, authored by CEO Jim Joyce, detailing the company's strategic initiatives including a potential merger and asset sales to navigate financial hurdles while advancing its dialysis-like therapies for cardiovascular disease and cancer.
Joyce, who previously founded Aethlon Medical and developed the FDA-cleared Hemopurifier, highlighted Sigyn's CardioDialysis platform, which targets cholesterol-transporting lipoproteins and inflammatory molecules. The device is designed for use on dialysis machines at over 7,500 clinics in the United States, offering a broader reach than current lipoprotein apheresis limited to fewer than 60 specialized centers. In vitro studies also suggest potential for treating traumatic brain injury and sepsis, the latter being a condition with no approved therapy.
The CEO acknowledged the company's financial struggles, noting that Sigyn became public through a merger with an OTC company but failed to uplist to Nasdaq due to a regulatory catch-22: Nasdaq required investor review before an effective SEC registration statement, while the SEC sought Nasdaq listing approval first. This led to the withdrawal of the registration statement for a firm commitment offering. To reduce shareholder dilution, Joyce outlined strategies including the sale of certain assets and a potential merger with a Nasdaq-listed company at risk of not meeting the $5 million minimum market value of listed securities requirement.
Joyce referenced a prior January 15 shareholder update for further details and emphasized that despite share price challenges, the company's therapeutic potential remains intact. He encouraged investors to follow Spectral Medical, whose PMX device is advancing in sepsis treatment, noting that CardioDialysis has been shown to reduce sepsis-inducing bacterial toxins and inflammatory mediators.
The update also disclosed that as of March 11, 2026, Sigyn had 2,330,042 shares outstanding. Joyce concluded by reiterating the company's commitment to advancing its pipeline, which includes ImmunePrep for immunotherapeutic antibodies, ChemoPrep for chemotherapy delivery, and ChemoPure to reduce chemotherapy toxicity.
For more information, visit the company's press release at Sigyn Therapeutics Shareholder Update or the original release on NewMediaWire.
